[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100524999":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":33,"locations":42,"responsibleParty":58,"collaborators":10,"id":61,"slug":10,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":10,"eligibilityCriteria":65,"healthyVolunteers":62,"sex":66,"minAge":67,"maxAge":10,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":78,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Dartmouth-Hitchcock Medical Center","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard of Care Checkpoint",null,"Patients receiving standard of care FDA approved immunotherapy",[13],"Diagnostic Test: Methylation Cytometry",{"label":15,"type":10,"description":16,"interventionNames":17},"Bone Marrow Transplant","Patients undergoing transplant for hematologic malignancy",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"CAR T","Patients undergoing CAR T therapy",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"DIAGNOSTIC_TEST","Methylation Cytometry","Assessment of the ability of Methylation Cytometry in pre-treatment peripheral blood and in repeated measures over the duration of treatment to predict treatment response or occurrence of adverse events.",[15,19,9],[29],{"name":30,"affiliation":31,"role":32},"Brock C Christensen, PhD","Dartmouth College","PRINCIPAL_INVESTIGATOR",[34,38],{"name":30,"role":35,"phone":36,"phoneExt":10,"email":37},"CONTACT","603-650-1827","brock.c.christensen@dartmouth.edu",{"name":39,"role":35,"phone":40,"phoneExt":10,"email":41},"Hannah G Stolrow, BA","7205174950","hannah.stolrow@dartmouth.edu",[43],{"facility":5,"status":44,"city":45,"state":46,"zip":47,"country":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Lebanon","New Hampshire","03756","United States",{"type":50,"coordinates":51},"Point",[52,53],-72.25176,43.64229,{"lat":53,"lon":52},[56,57],{"name":39,"role":35,"phone":40,"phoneExt":10,"email":41},{"name":30,"role":32,"phone":10,"phoneExt":10,"email":10},{"type":32,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Brock C. Christensen","Professor of Epidemiology, Molecular and Systems Biology, and of Community and Family Medicine","100524999",false,"NCT06116032","Immune Profiling for Cancer Immunotherapy Response","Inclusion Criteria:\n\n* Cancer patients receiving or will receive immunotherapy under FDA- approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy).\n* Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included).\n\nExclusion Criteria:\n\n* Pregnant women\u002Ffetuses\u002Fneonates\n* Prisoners\n* Decision-impaired individuals","ALL","18 Years",{"count":69,"type":70},1500,"ESTIMATED","OBSERVATIONAL","In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.",[74,75,76,77],"Cancer","Tumor, Solid","Hematologic Malignancy","Blood Cancer",[79],"Immunotherapy","2025-12-09",{"date":82,"type":83},"2025-12-16","ACTUAL",{"date":85,"type":83},"2022-10-03",{"date":87,"type":70},"2029-01-01",{"name":5,"class":6},1]